Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 15
Chunk 21
---
 Committee regarding our engagement
of the independent auditor, provided the policies and procedures are detailed as to the particular service, the Audit Committee is informed
of each service provided and such policies and procedures do not include delegation of the Audit Committee’s responsibilities under
the Exchange Act to management. Audit Committee pre-approval of non-audit services (other than review and attest services) also will not
be required if such services fall within available exceptions established by the SEC.

  115  

  Table of Contents  

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES.

Not applicable.

ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS.

None.

ITEM 16F. CHANGE IN REGISTRANT’ S CERTIFYING ACCOUNTANTS.

The information required by
this Item 16F was previously reported in our Report on Form 6-K filed with the SEC on November 1, 2024, which is incorporated herein by
reference.

ITEM 16G. CORPORATE GOVERNANCE.

Companies with securities
listed on NASDAQ are required to comply with United States federal securities laws, including the Sarbanes-Oxley Act of 2002, as well
as certain NASDAQ rules and corporate governance requirements. As a foreign private issuer, however, we are entitled to follow our home
country practice in lieu of the NASDAQ corporate governance standards, subject to certain exceptions and except to the extent that such
exemptions would be contrary to United States federal securities laws. The United Kingdom laws and practices followed by the Company in
lieu of NASDAQ rules are described below:

  We do not follow NASDAQ’s requirement that the Board of Directors be comprised of a majority of                                            

  We do not follow NASDAQ’s requirements applicable to independent director oversight of director                                          
  nominations, which require that director nominees either be selected or recommended by independent directors. In accordance with United  
  Kingdom law and practice, our directors are nominated by the Nominations Committee, which is comprised of all of the directors of the    
  Company.                                                                                                                                 
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We do not follow NASDAQ’s requirement that the compensation committee be comprised of Independent  

  We do not require that the compensation committee consider the specific factors affecting consultant independence                               

  We do not follow NASDAQ’s requirements that non